News and Views

Drug Reference Sheets

Oncology Drug Reference Sheet: Loncastuximab Tesirine-Lpyl

Based on LOTIS-2 trial results that reported an overall response rate of nearly 50%, in April 2021 the U.S. Food and Drug Administration granted accelerated approval to loncastuximab tesirine-lpyl (Zynlonta^TM) for adults with relapsed or refractory large B-cell lymphoma.

Trending Topics

View All Topics

Digital Health Literacy Affects Overall Survival in Adults With Cancer

Cancer Research

Digital Health Literacy Affects Overall Survival in Adults With Cancer

Margaret Hansen Frogge Receives 2022 Lifetime Achievement Award at 47th Annual ONS Congress

Margaret Hansen Frogge Receives 2022 Lifetime Achievement Award at 47th Annual ONS Congress

Catherine Lyons Posthumously Receives 2022 Lifetime Achievement Award at 47th Annual ONS Congress

Catherine Lyons Posthumously Receives 2022 Lifetime Achievement Award at 47th Annual ONS Congress

Maintain Oral Adherence With ONS Guidelines™

Maintain Oral Adherence With ONS Guidelines™

Pediatric Patients With Cancer Are Vulnerable to Sleep Disturbance

Patient Quality of Life

Pediatric Patients With Cancer Are Vulnerable to Sleep Disturbance

FDA Reports Recall of Milk of Magnesia Oral Suspension and Magnesium Hydroxide/Aluminum Hydroxide/Simethicone Oral Suspension

U.S. Food and Drug Administration (FDA)

FDA Reports Recall of Milk of Magnesia Oral Suspension and Magnesium Hydroxide/Aluminum Hydroxide/Simethicone Oral Suspension

Independent Advocates Help Patients With Dementia Navigate Cancer Care

Care Coordination

Independent Advocates Help Patients With Dementia Navigate Cancer Care

Erica Fischer-Cartlidge, DNP, CNS, AOCNS®, EBP-C

ONS Hires Erica Fischer-Cartlidge, DNP, CNS, AOCNS®, EBP-C, as Chief Clinical Officer

Childhood Cancer Survivors Have Healthy but Riskier Pregnancies

Cancer Research

Childhood Cancer Survivors Have Healthy but Riskier Pregnancies

Special Populations

Cancer Health Disparities

Special Populations

Collaborations Advance ONS’s Goals and Innovation

Collaborations Advance ONS’s Goals and Innovation

FDA Reports Illumina Cybersecurity Vulnerability May Present Risks for Patient Results and Customer Networks

U.S. Food and Drug Administration (FDA)

FDA Reports Illumina Cybersecurity Vulnerability May Present Risks for Patient Results and Customer Networks

FDA Withdraws Approval of Umbralisib Because of Safety Concerns

U.S. Food and Drug Administration (FDA)

FDA Withdraws Approval of Umbralisib Because of Safety Concerns

$FDA Approves Tisagenlecleucel for Relapsed or Refractory Follicular Lymphoma$

U.S. Food and Drug Administration (FDA)

FDA Approves Tisagenlecleucel for Relapsed or Refractory Follicular Lymphoma

FDA Approves Nivolumab in Combination With Chemotherapy and in Combination With Ipilimumab for First-Line Esophageal Squamous Cell Carcinoma Indications

U.S. Food and Drug Administration (FDA)

FDA Approves Nivolumab in Combination With Chemotherapy and in Combination With Ipilimumab for First-Line Esophageal Squamous Cell Carcinoma Indications

Naive T-Cell Depletion Prevents Chronic GVHD in Transplantation Survivors

Cancer Research

Naive T-Cell Depletion Prevents Chronic GVHD in Transplantation Survivors

Rest, Unwind, and Reflect so You Can Lead by Example

Nurse Well-Being

Rest, Unwind, and Reflect so You Can Lead by Example

FDA Approves Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia

U.S. Food and Drug Administration (FDA)

FDA Approves Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia

Spring Clean Your Home and Heart

Nurse Well-Being

Spring Clean Your Home and Heart

Cutaneous Malignancies Have High Response to Oncolytic Virus Plus Immunotherapy

Cancer Research

Cutaneous Malignancies Have High Response to Oncolytic Virus Plus Immunotherapy

Oncology Drug Reference Sheet: Belumosudil

Drug Reference Sheets

Oncology Drug Reference Sheet: Belumosudil

FDA Approves Azacitidine for Newly Diagnosed Juvenile Myelomonocytic Leukemia

U.S. Food and Drug Administration (FDA)

FDA Approves Azacitidine for Newly Diagnosed Juvenile Myelomonocytic Leukemia

E-Cigarettes Increase Risk of Lung and Bladder Cancer More Than Traditional Cigarettes

Cancer Research

E-Cigarettes Increase Risk of Lung and Bladder Cancer More Than Traditional Cigarettes

Use the Evidence to Integrate Ethics in Teleoncology Care

Oncology Nurse-Patient Relationship

Use the Evidence to Integrate Ethics in Teleoncology Care

Don’t Ask Patients About Their Symptoms—Have Them Tell You

Symptom Management

Don’t Ask Patients About Their Symptoms—Have Them Tell You

AI Ultrasound Is Nearly 100% Accurate in Detecting Thyroid Cancers

Cancer Research

AI Ultrasound Is Nearly 100% Accurate in Detecting Thyroid Cancers

Oncology Navigation Standards Help Patients Overcome Disparities and Barriers to Care

Cancer Health Disparities

Oncology Navigation Standards Help Patients Overcome Disparities and Barriers to Care

Studies Show Best Practices to Manage CAR T-Cell Therapies’ irAEs and Improve Outcomes

Studies Show Best Practices to Manage CAR T-Cell Therapies’ irAEs and Improve Outcomes

FDA Grants Regular Approval to Fam-Trastuzumab Deruxtecan-Nxki for Breast Cancer

U.S. Food and Drug Administration (FDA)

FDA Grants Regular Approval to Fam-Trastuzumab Deruxtecan-Nxki for Breast Cancer

Oncology Clinical Social Workers Add Layers of Support for Patients and Families During CAR T-Cell Therapy

Patient Support

Oncology Clinical Social Workers Add Layers of Support for Patients and Families During CAR T-Cell Therapy

More Patients Are Skipping Their Cervical Cancer Screenings

More Patients Are Skipping Their Cervical Cancer Screenings

CAR T-Cell Therapy Programs

Cancer Treatments

CAR T-Cell Therapy Programs

Remember Your Passion, Your Purpose, and the Heart of Oncology Nursing

Remember Your Passion, Your Purpose, and the Heart of Oncology Nursing

Empower Your Nurses With Appreciation in Celebration of Oncology Nursing Month

Nurse Well-Being

Empower Your Nurses With Appreciation in Celebration of Oncology Nursing Month

ONS Announces 2022 Award Recipients at 47th Annual ONS Congress® in Anaheim

ONS Announces 2022 Award Recipients at 47th Annual ONS Congress® in Anaheim

Targeting Beta2-Spectrin Could Prevent Biggest Contributor to Increasing HCC Rates

Cancer Research

Targeting Beta2-Spectrin Could Prevent Biggest Contributor to Increasing HCC Rates

Oncology Drug Reference Sheet: Avapritinib

Drug Reference Sheets

Oncology Drug Reference Sheet: Avapritinib

First-Line Combination Immunotherapy Prolongs Survival in BRAF Advanced Melanoma

Cancer Research

First-Line Combination Immunotherapy Prolongs Survival in BRAF Advanced Melanoma

Anticipate and Address Anxiety in Survivorship Care

Oncology Nurse-Patient Relationship

Anticipate and Address Anxiety in Survivorship Care

APRN Roles Evolve to Address Cancer Screening, Treatment Adherence, and Public Health

Advanced Practice Nursing (APRN)

APRN Roles Evolve to Address Cancer Screening, Treatment Adherence, and Public Health

Breast-Conserving Surgery Leads to Better QOL for Young Breast Cancer Survivors

Breast-Conserving Surgery Leads to Better QOL for Young Breast Cancer Survivors

Climate Change Is Contributing to the Cancer Burden, and Nurses Must Take Action

Oncology Nursing Roles

Climate Change Is Contributing to the Cancer Burden, and Nurses Must Take Action

Genetic Disorder Reference Sheet: Von Hippel-Lindau Syndrome

Genetics & Genomics

Genetic Disorder Reference Sheet: Von Hippel-Lindau Syndrome

FDA Approves Alpelisib for PIK3CA-Related Overgrowth Spectrum

U.S. Food and Drug Administration (FDA)

FDA Approves Alpelisib for PIK3CA-Related Overgrowth Spectrum

What Patients and Oncology Nurses Need to Know About Vaccination and Cancer

Patient Resources

What Patients and Oncology Nurses Need to Know About Vaccination and Cancer

E-Cigarettes Are Not an Effective Smoking Cessation Strategy

Cancer Research

E-Cigarettes Are Not an Effective Smoking Cessation Strategy

Home Care and Oncology Nurses Partner to Expand Ambulatory Options for Patients With Cancer

Care Coordination

Home Care and Oncology Nurses Partner to Expand Ambulatory Options for Patients With Cancer

FDA Approves Axicabtagene Ciloleucel for Second-Line Treatment of Large B-Cell Lymphoma

U.S. Food and Drug Administration (FDA)

FDA Approves Axicabtagene Ciloleucel for Second-Line Treatment of Large B-Cell Lymphoma

The Evolution of Ambulatory Care

Care Coordination

The Evolution of Ambulatory Care

Back to Top ▲